Samsung bioepis and biogen receive european commission (ec) approval for aflibercept biosimilar, opuviz™

Incheon, south korea and cambridge, mass., nov. 18, 2024 (globe newswire) -- samsung bioepis co., ltd. and biogen inc. (nasdaq: biib) today announced that the european commission (ec) has approved opuviz™ 40 mg/ml solution for injection in a vial, a biosimilar referencing eylea1,2 (aflibercept), developed and registered by samsung bioepis.
EC Ratings Summary
EC Quant Ranking